New drug for schizophrenics has experts excited

The drug, called Cobenfy and developed by US pharma giant Bristol Myers Squibb, works differently from existing treatments, targeting the so-called cholinergic receptors, not the dopamine receptors.

Two clinical trials confirmed its effectiveness, showing it can significantly reduce patients' symptoms. File photo